Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam dose comparison with alfentanil for painless gastroscopy in elderly patients
ChiCTR2400085695Phase 4Not yet recruiting
- Sponsor
- Central Hospital Affiliated to Shandong First Medical University
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of remimazolam, alfentanil and propofol in gastrointestinal conditions (4 arms), sponsored by Central Hospital Affiliated to Shandong First Medical University. Primary endpoint: Success rate of first dose sedation. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
remimazolamalfentanilpropofol
03
Conditions
gastrointestinal conditions
Beyond the preview
Go deeper on ChiCTR2400085695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085695.